Microbiotica announces that the first patient has been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.
Rinri Therapeutics, which is focused on transforming hearing loss treatment with regenerative cell therapy, announces that the novel surgical procedure to be used for regenerative cell delivery in its first-in-human trial has been published in the prestigious journal Nature Scientific Reports.
NRG Therapeutics, Ltd has achieved a key milestone with the nomination of its first development candidate, NRG5051 and has been awarded a $5M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
Astex Pharmaceuticals announced today that it will make five key data presentations at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics, 23rd-25th October 2024, Barcelona, Spain.
Ikarovec’s seed round extension raises funds to continue advanced pre-clinical trials of novel gene therapies to treat blindness and major chronic eye disease.
Today marks a pivotal moment for our Association as a key strategic objective has been realised: the new government has placed growth at the centre of its agenda, with life sciences positioned as a cornerstone of that plan.
Microbiotica announces that the first patient has been dosed in its advanced melanoma (MELODY-1) trial. This international trial is due to recruit up to 40 patients at clinical centres in the UK, France, Italy and Spain. Initial data readouts are expected by the end of 2025.
The BIA’s policy and public affairs team attended the conferences of the three major UK parties this year. This is a key point in the political calendar and allows us to highlight the sector through fringe events, meet policymakers, and get a sense of the political environment.
Cancer Research UK and NovalGen have signed an agreement to bring NovalGen’s next-generation T-cell engager, NVG-222, into a first-in-human clinical trial.
This year RNID have been chosen as the BIA’s charity partner of the year. This partnership gives us a unique platform to shine the light on the huge opportunities that exist for hearing therapeutics.
